目的: 评价乳腺浸润性导管癌组织COX-2 蛋白的表达情况及其与相关临床或病理参数间的相关
性. 方法: 取101 例资料完整的乳腺浸润性导管癌手术切除标本为研究对象 …

Immune responses influence the development and progression of a malignancy. The tumour
can also manipulate the immune system to its own ends, often resulting in an ineffective or …

Background/Aim: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has
limited anticancer efficacy in EGFR-positive esophageal cancer (EsC) and malignant …

Several methods for comparing k populations have been proposed in the literature. These
methods assess the same null hypothesis of equal distributions but differ in the alternative …

Celecoxib (CelebrexR) is a cyclooxygenase-2 (COX-2) selective inhibitor and gefitinib
(IressaR, ZD1839) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase …

Background The hepatocyte growth factor (HGF)/c-Met pathway is often dysregulated in non–
small-cell lung cancer (NSCLC). HGF activation of c-Met induces cyclooxygenase-2 (COX …

Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early
event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with …

Efficacy of erlotinib and celecoxib for patients with advanc... : Medicine Efficacy of erlotinib and
celecoxib for patients with advanced non-small cell lung cancer: A retrospective study : Medicine …

For molecularly targeted therapy and immunotherapy, the targeted dose in the early phase
clinical trial has been shifted from the maximum tolerated dose for the cytotoxic drug to the …

There are considerable preclinical and clinical data showing that cyclooxygenase-2 (COX-2)
plays an important role in the pathogenesis of non–small-cell lung cancers (NSCLC). 1, 2 …